Ocugen (OCGN) Total Non-Current Liabilities (2014 - 2026)
Ocugen (OCGN) reported Total Non-Current Liabilities of $30.4 million for Q1 2026, down 4.01% on a YoY basis from $31.7 million in Q1 2025, and down 6.88% quarter-over-quarter from $32.6 million in Q4 2025.
Ocugen (OCGN) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Ocugen has reported Total Non-Current Liabilities for 13 years, with the latest figure at $30.4 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 4.01% year-over-year to $30.4 million; the trailing twelve-month figure through Mar 2026 stood at $30.4 million (down 4.01% YoY), and the FY2025 full-year result was $32.6 million, up 4.54% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $30.4 million, down from $32.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $33.7 million in Q3 2025, with the low at $2.9 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $14.8 million across 5 years, with a median of $6.0 million in 2022.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities dropped 14.48% — and 2025, when it jumped 507.9%.
- Ocugen's Total Non-Current Liabilities stood at $6.1 million in 2022, then increased by 12.65% to $6.9 million in 2023, then surged by 352.89% to $31.2 million in 2024, then rose by 4.54% to $32.6 million in 2025, then retreated by 6.88% to $30.4 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $30.4 million (Q1 2026), $32.6 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | 30.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.39 Mn |
| Dec 31, 2025 | 32.64 Mn |
| Sep 30, 2025 | 33.70 Mn |
| Jun 30, 2025 | 32.55 Mn |
| Mar 31, 2025 | 31.66 Mn |
| Dec 31, 2024 | 31.22 Mn |
| Sep 30, 2024 | 5.54 Mn |
| Jun 30, 2024 | 5.64 Mn |
| Mar 31, 2024 | 5.48 Mn |
| Dec 31, 2023 | 6.89 Mn |
| Sep 30, 2023 | 5.16 Mn |
| Jun 30, 2023 | 5.24 Mn |
| Mar 31, 2023 | 4.82 Mn |
| Dec 31, 2022 | 6.12 Mn |
| Sep 30, 2022 | 6.03 Mn |
| Jun 30, 2022 | 5.64 Mn |
| Mar 31, 2022 | 2.91 Mn |
| Dec 31, 2021 | 2.94 Mn |
| Sep 30, 2021 | 2.97 Mn |
| Jun 30, 2021 | 3.00 Mn |